Latest News

Suven Pharmaceuticals to become Cohance Lifesciences, symbol changes to COHANCE from May 19

Source |12:26 13 May 25

corporate actions

The National Stock Exchange of India has announced that the name and symbol of Suven Pharmaceuticals Limited will change effective from May 19, 2025.

The existing symbol SUVENPHAR will be changed to COHANCE.
The existing name Suven Pharmaceuticals Limited will be changed to Cohance Lifesciences Limited.

SUVENPHAR

Suven Pharma (Now Cohance Lifesciences) Allots 12.80 Crore Shares Post Amalgamation

Source |03:31 09 May 25

mergers & acquisitions

Suven Pharmaceuticals Limited, now known as Cohance Lifesciences Limited effective May 7, 2025, has announced the allotment of 12,80,02,184 equity shares of face value ₹1 each on May 9, 2025.

These shares were allotted to eligible shareholders of Cohance Lifesciences Limited (the Transferor Company) as on the Record Date (April 25, 2025) as per the Scheme of Amalgamation.
The share exchange ratio is 11 fully paid-up equity shares of ₹1 each of Suven Pharma (now Cohance Lifesciences) for every 295 fully paid-up equity shares of ₹10 each held in Cohance Lifesciences Limited.
The allotted shares rank pari-passu with existing equity shares and are proposed to be listed on BSE and NSE.
The allotment includes 18 shares to the Fractional Share Demat Account and 34,906 shares to the Unclaimed Securities – Suspense Escrow account for fractional entitlements and unclaimed shares, respectively.

SUVENPHAR

Suven Pharma changes name to Cohance Lifesciences post-amalgamation.

Source |06:01 07 May 25

mergers & acquisitions corporate actions regulatory filings

Suven Pharmaceuticals Limited announced that the Ministry of Corporate Affairs (MCA) has approved the change of the company's name to "Cohance Lifesciences Limited", effective from 7 May 2025. * This change is pursuant to the Scheme of Amalgamation for the merger of Cohance Lifesciences Limited with Suven Pharmaceuticals Limited, which was approved by the National Company Law Tribunal (NCLT) on 27 March 2025. * The company will apply to BSE and NSE to effect the change of name. * The Memorandum of Association and Articles of Association will be updated to reflect the new name.

SUVENPHAR

Suven Pharma Announces Analyst and Investor Roadshows in Hong Kong and Singapore

Source |03:24 28 Apr 25

regulatory filings corporate actions

Suven Pharmaceuticals Limited will be attending analyst and institutional investor roadshows in Hong Kong and Singapore. The roadshows are scheduled as follows:

Hong Kong: Organized by B&K from 31 Mar 25 to 01 Apr 25.
Singapore: Organized by Macquarie from 02 Apr 25 to 03 Apr 25.

The company has stated that no unpublished price-sensitive information will be shared during these interactions. The schedule is subject to change.

SUVENPHAR

Suven Pharmaceuticals Board Meeting on 28 May 25 to Approve Financial Results; Trading Window Closure Announced

Source |03:24 28 Apr 25

results corporate actions regulatory filings

Suven Pharmaceuticals (SUVENPHAR) will hold a Board Meeting on 28 May 25 to consider and approve the audited financial results (standalone and consolidated) for the quarter and financial year ending 31 Mar 25.

Additionally, the trading window for dealing in the company's securities will be closed from 1 Apr 25 to 30 May 25.